دورية أكاديمية
أعرض في EDS

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

التفاصيل البيبلوغرافية
العنوان: Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
المؤلفون: Flaxman A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Sebastian S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Appelberg S; Public Health Agency of Sweden, Solna, Sweden., Cha KM; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Ulaszewska M; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Purushotham J; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Gilbride C; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Sharpe H; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Spencer AJ; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Wright D; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Schmidt I; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Dowall S; UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom., Easterbrook L; UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom., Findlay-Wilson S; UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom., Gilbert S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Mirazimi A; Public Health Agency of Sweden, Solna, Sweden., Lambe T; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.; Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford, United Kingdom.
المصدر: PLoS pathogens [PLoS Pathog] 2024 Jun 26; Vol. 20 (6), pp. e1012262. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: Ebolavirus*/immunology , Lassa virus*/immunology , Marburgvirus*/immunology , Hemorrhagic Fever, Ebola*/prevention & control , Hemorrhagic Fever, Ebola*/immunology , Lassa Fever*/immunology , Lassa Fever*/prevention & control , Marburg Virus Disease*/immunology , Marburg Virus Disease*/prevention & control, Animals ; Mice ; Viral Vaccines/immunology ; Humans ; Vaccination ; Female ; Antibodies, Viral/immunology ; Immunogenicity, Vaccine ; Ebola Vaccines/immunology
مستخلص: Viral haemorrhagic fevers (VHF) pose a significant threat to human health. In recent years, VHF outbreaks caused by Ebola, Marburg and Lassa viruses have caused substantial morbidity and mortality in West and Central Africa. In 2022, an Ebola disease outbreak in Uganda caused by Sudan virus resulted in 164 cases with 55 deaths. In 2023, a Marburg disease outbreak was confirmed in Equatorial Guinea and Tanzania resulting in over 49 confirmed or suspected cases; 41 of which were fatal. There are no clearly defined correlates of protection against these VHF, impeding targeted vaccine development. Any vaccine developed should therefore induce strong and preferably long-lasting humoral and cellular immunity against these viruses. Ideally this immunity should also cross-protect against viral variants, which are known to circulate in animal reservoirs and cause human disease. We have utilized two viral vectored vaccine platforms, an adenovirus (ChAdOx1) and Modified Vaccinia Ankara (MVA), to develop a multi-pathogen vaccine regime against three filoviruses (Ebola virus, Sudan virus, Marburg virus) and an arenavirus (Lassa virus). These platform technologies have consistently demonstrated the capability to induce robust cellular and humoral antigen-specific immunity in humans, most recently in the rollout of the licensed ChAdOx1-nCoV19/AZD1222. Here, we show that our multi-pathogen vaccines elicit strong cellular and humoral immunity, induce a diverse range of chemokines and cytokines, and most importantly, confers protection after lethal Ebola virus, Sudan virus and Marburg virus challenges in a small animal model.
Competing Interests: TL reports consulting fees from Vaccitech on an unrelated project, an honorarium from Seqirus, grant support from the DHSC for this work, and is named as an inventor on a patent application for a vaccine against SARS-CoV-2. SG is named as an inventor on patents covering use of ChAdOx1-vectored vaccines and a vaccine against SARS-CoV-2.
(Copyright: © 2024 Flaxman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Genome Biol. 2014;15(11):540. (PMID: 25416632)
NPJ Vaccines. 2021 Mar 2;6(1):32. (PMID: 33654106)
J Infect Dis. 2018 Nov 22;218(suppl_5):S312-S317. (PMID: 29889270)
Nat Med. 2014 Oct;20(10):1126-9. (PMID: 25194571)
EBioMedicine. 2023 Mar;89:104463. (PMID: 36774693)
N Engl J Med. 2016 Apr 28;374(17):1635-46. (PMID: 25629663)
Lancet Microbe. 2023 Mar;4(3):e171-e178. (PMID: 36739878)
NPJ Vaccines. 2018 Mar 20;3:11. (PMID: 29581897)
J Vector Borne Dis. 2007 Mar;44(1):1-11. (PMID: 17378212)
Infect Immun. 2010 Jan;78(1):145-53. (PMID: 19858306)
Curr Opin Immunol. 2015 Aug;35:131-6. (PMID: 26247875)
Methods Mol Biol. 2017;1581:97-119. (PMID: 28374245)
J Immunol. 2011 Sep 1;187(5):2602-16. (PMID: 21813775)
J Infect Dis. 2024 Mar 15;:. (PMID: 38487996)
Lancet. 2017 Feb 4;389(10068):505-518. (PMID: 28017403)
Vaccines (Basel). 2019 Jan 22;7(1):. (PMID: 30678246)
Comp Med. 2017 Jun 1;67(3):253-262. (PMID: 28662754)
Lancet. 2017 Dec 16;390(10113):2662-2672. (PMID: 29031848)
PLoS One. 2012;7(7):e40385. (PMID: 22808149)
J Virol. 2012 Mar;86(6):3389-92. (PMID: 22238311)
Nat Med. 1999 Apr;5(4):423-6. (PMID: 10202932)
Viruses. 2015 Oct 23;7(10):5489-507. (PMID: 26512687)
NPJ Vaccines. 2020 Dec 17;5(1):112. (PMID: 33335092)
N Engl J Med. 2019 Dec 12;381(24):2293-2303. (PMID: 31774950)
PLoS One. 2013 Aug 22;8(8):e72290. (PMID: 23991083)
PLoS Pathog. 2009 Jul;5(7):e1000536. (PMID: 19649327)
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736. (PMID: 25884628)
PLoS Med. 2005 Jun;2(6):e183. (PMID: 15971954)
Eur J Immunol. 2013 Jul;43(7):1940-52. (PMID: 23589155)
PLoS Med. 2017 May 16;14(5):e1002300. (PMID: 28510604)
Virology (Auckl). 2019 Jun 21;10:1178122X19849927. (PMID: 31258326)
J Infect Dis. 2015 Oct 1;212 Suppl 2:S384-8. (PMID: 25957964)
J Immunol. 2017 Jul 19;:. (PMID: 28724579)
Sci Rep. 2013;3:1443. (PMID: 23485942)
Nat Med. 2011 Aug 21;17(9):1128-31. (PMID: 21857654)
N Engl J Med. 2018 Nov 1;379(18):1745-1753. (PMID: 30332564)
PLoS One. 2008 Feb 20;3(2):e1638. (PMID: 18286194)
Front Immunol. 2015 Jul 20;6:367. (PMID: 26257735)
Genome Announc. 2014 Nov 20;2(6):. (PMID: 25414499)
Sci Rep. 2016 May 03;6:25280. (PMID: 27140942)
المشرفين على المادة: 0 (Viral Vaccines)
0 (Antibodies, Viral)
0 (Ebola Vaccines)
تواريخ الأحداث: Date Created: 20240626 Date Completed: 20240709 Latest Revision: 20240711
رمز التحديث: 20240711
مُعرف محوري في PubMed: PMC11233014
DOI: 10.1371/journal.ppat.1012262
PMID: 38924060
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1012262